ProJenX
ProJenX is a clinical-stage biopharmaceutical company developing prosetin, a first-in-class CNS-penetrant MAP4K inhibitor for ALS, plus pipeline candidates for Parkinson's, Alzheimer's, and glioblastoma. Spun out of Columbia University and Project ALS, the company is conducting global Phase 1 trials.
- Company typePrivate
- Founded2022
- HeadquartersNew Suffolk, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What ProJenX does
ProJenX is a clinical-stage biopharmaceutical company developing brain-penetrant small molecule therapeutics that target motor neuron degenerative pathways, with its lead candidate prosetin positioned as the first-in-class CNS-penetrant MAP4K inhibitor to enter clinical trials for ALS. The company was founded in February 2022 as a spin-out of a more than twenty-year research collaboration between Project ALS, a nonprofit founded in 1998 by the Estess family, and Columbia University researchers at the Center for Motor Neuron Biology and Disease and the Eleanor and Lou Gehrig ALS Center. ProJenX is headquartered in New York City, employs 1-10 people, and is led by President and CEO Stan Abel, with Erin Fleming as Co-Founder and Chief Operating Officer and Rick Hartz (formerly SVP at Merck) on the board.
The company's core technology is a patient-specific, cell-based drug discovery platform in which motor neurons derived from skin or blood samples of people with ALS are used to identify compounds that rescue endoplasmic reticulum stress-mediated motor neuron loss. Prosetin, the lead clinical asset, is an oral, selective, brain-penetrant small molecule that inhibits MAP4K and is being evaluated in PRO-101, a hybrid Phase 1 trial across the United States, Canada, and the European Union. As of mid-2026, 41 ALS participants had been enrolled across five dose levels in Phase 1b, with interim data showing target therapeutic exposure, statistically significant target engagement (pMAP2K4 reduction in PBMCs), and no serious adverse events across an open-label extension. Beyond prosetin, the disclosed pipeline includes MAP4K inhibitor candidates for Parkinson's disease, glioblastoma, and Alzheimer's disease, plus an undisclosed second ALS candidate, all leveraging the same ER stress mechanism.
ProJenX is pre-revenue and does not yet commercialize any product. The revenue model contemplates future one-time licensing or partnered commercialization, with prescription sales through specialty pharmacies as the most likely post-approval distribution pathway. Customer concentration is by design on a single asset and a single primary indication (ALS), supported by an international Clinical Advisory Board chaired by Angela Genge and including Jinsy Andrews, Leonard van den Berg, and Merit Cudkowicz. The company has raised approximately $21.1 million to date across a $5.1M seed (February 2022), a $15M Series A (November 2023), and a $1M Hoffman ALS Clinical Trial Award grant from the ALS Association (June 2024), with Medical Excellence Capital leading both equity rounds. AI is not a core capability of ProJenX itself; however, the September 2024 partnership with Unlearn deploys AI-generated digital twins as placebo controls in PRO-101, positioning the program to potentially run a more efficient late-stage trial.
ProJenX firmographics
Firmographics- Name
- ProJenX
- Legal name
- ProJenX, Inc.
- Website
- https://projenx.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- ProJenX is a clinical-stage biopharmaceutical company developing prosetin, a first-in-class CNS-penetrant MAP4K inhibitor for ALS, plus pipeline candidates for Parkinson's, Alzheimer's, and glioblastoma. Spun out of Columbia University and Project ALS, the company is conducting global Phase 1 trials.
- Ownership category
- akta.pro rank
ProJenX industry classification
Industry- Product category
- Neurological Therapeutics (ALS)
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where ProJenX is headquartered
LocationHeadquarters
- HQ city
- New Suffolk
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
ProJenX business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Drug Development and Commercialization: ProJenX is a pre-revenue clinical-stage biotechnology company. The company is developing prosetin through clinical trials for ALS treatment. Revenue generation will occur upon FDA approval and commercialization of prosetin, likely through prescription sales via specialty pharmacies and potentially partnered distribution.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
ProJenX product offering
Product offeringCore offering
ProJenX is developing prosetin, a novel, orally bioavailable, CNS-penetrant small-molecule MAP4K inhibitor intended as a disease-modifying treatment for ALS by reducing endoplasmic reticulum stress-mediated motor neuron loss. The company is advancing prosetin through a hybrid Phase 1 clinical trial (PRO-101) in healthy volunteers and ALS patients and is building an additional pipeline of MAP4K inhibitor candidates for Parkinson's disease, glioblastoma, and Alzheimer's disease.
Product overview
ProJenX is a clinical-stage biotechnology company developing a portfolio of novel, brain-penetrant MAP4K inhibitors for neurodegenerative diseases. The company's core product is prosetin, a first-in-class oral MAP4K inhibitor currently in Phase 1 clinical trials for ALS, which achieved positive interim safety and target engagement data in 2026. The company is also advancing prosetin for Parkinson's disease, glioblastoma, and Alzheimer's disease, plus an undisclosed second ALS candidate, leveraging a patient-specific cell-based drug discovery platform developed with Columbia University and Project ALS.
Differentiator
Problem solved
Functional benefit
Products and services
- Prosetin Prosetin is a novel, oral, CNS-penetrant, first-in-class small-molecule MAP4K inhibitor designed as a disease-modifying treatment for ALS by reducing endoplasmic reticulum (ER) stress-mediated motor neuron loss. It is being evaluated in the PRO-101 hybrid Phase 1 trial and is intended for people diagnosed with either sporadic or familial ALS.
Quantifiable outcome
- Target therapeutic exposure achieved at two highest dose levels (0.70 and 1.05 mg/kg/day) in Phase 1b ALS participants
- +2 more outcomes
Companies that use ProJenX
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
ProJenX technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
ProJenX partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- UnlearncoreProJenX partnered with Unlearn to implement their ALS-Digital Twin Generator (ALS-DTG) in the PRO-101 clinical trial. The AI-powered digital twins serve as placebo controls for trial participants, enabling more efficient evaluation of prosetin's effects on ALS disease progression by comparing dosed participants to their digitally generated placebo versions.
- Project ALScoreProject ALS, a nonprofit organization founded in 1998 by Jenifer Estess and her family, collaborated with Columbia University researchers for over 20 years to develop prosetin. ProJenX was spun out from this collaboration to advance prosetin through clinical trials. Project ALS funded preclinical development and continues to support the program.
- Columbia UniversitycoreColumbia University researchers at the Center for Motor Neuron Biology and Disease and Eleanor and Lou Gehrig ALS Center developed the patient-specific cell-based discovery platform and discovered prosetin. Researchers from Departments of Pathology & Cell Biology, Biological Sciences, and Chemistry collaborated on the drug discovery program.
Scale indicators5 records
Recent moves7 records
Expansion highlights6 records
ProJenX competitors and assessment
Company assessmentDirect peers
- Ionis Pharmaceuticals: Ionis is developing antisense oligonucleotide therapies for ALS, including BIIB078 (C9orf72) and its broader neurology pipeline. It is directly comparable to ProJenX as a CNS-focused, clinical-stage developer of disease-modifying ALS therapeutics.
- Cytokinetics: Cytokinetics is a clinical-stage biopharmaceutical company with a longstanding ALS program (reldesemtiv, though discontinued in Phase 3) and ongoing pipeline in muscle biology. It is a direct peer in late-stage ALS clinical development strategy.
- AcuraStem: AcuraStem is a patient-derived iPSC drug discovery company developing AS-202, an antisense therapy for sporadic and familial ALS. Its patient-derived discovery platform and ALS focus make it highly comparable to ProJenX's approach.
- Clene Nanomedicine: Clene is a clinical-stage biotech developing CNM-Au8, a gold nanocatalyst for ALS and other neurodegenerative diseases. It is a direct peer as a small-cap, late-clinical-stage company targeting disease modification in ALS.
Broad incumbents
- Biogen: Biogen is the leading ALS-focused biopharmaceutical company following its 2023 FDA approval of Qalsody (tofersen) for SOD1-ALS. It serves as both a benchmark for ALS commercial viability and a potential acquirer of complementary ALS assets like prosetin.
Emerging players
- Helixmith: Helixmith is developing Engensis (VM202), a gene therapy for ALS and diabetic neuropathy. It is comparable as a small clinical-stage biotech pursuing disease-modifying treatments in ALS through a novel biological mechanism.
- Denali Therapeutics: Denali is a clinical-stage biotech developing brain-penetrant small molecules for neurodegenerative diseases, including ALS programs (e.g., DNL343). It is comparable as a fellow brain-penetrant CNS biotech with kinase/enzymatic pathway targeting.
- AB Science: AB Science is developing masitinib, a tyrosine kinase inhibitor, for ALS. Although in late-stage development, it represents the closest mechanism-class analog to ProJenX as a small-molecule kinase-targeting therapy in ALS.
- Eledon Pharmaceuticals: Eledon is a clinical-stage biotech developing tegoprubart, an anti-CD40L antibody, for ALS and other indications. It is a peer as a small-cap clinical-stage company targeting ALS with a novel immunomodulatory mechanism.
- Praxis Precision Medicines: Praxis is a clinical-stage CNS biotech with multiple precision neuroscience programs. While focused on epilepsy and movement disorders, it is comparable as a small-cap, CNS-focused, clinically advanced biotech with similar capital and team structure.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
ProJenX social profiles
Digital presenceProJenX financial estimates
Financial estimateRevenue estimate
Valuation estimate
ProJenX leadership team
Management profileNumber of profiles
Profiles4 records
ProJenX funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ProJenX M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ProJenX
What does ProJenX do?
ProJenX is developing prosetin, a novel, orally bioavailable, CNS-penetrant small-molecule MAP4K inhibitor intended as a disease-modifying treatment for ALS by reducing endoplasmic reticulum stress-mediated motor neuron loss. The company is advancing prosetin through a hybrid Phase 1 clinical trial (PRO-101) in healthy volunteers and ALS patients and is building an additional pipeline of MAP4K inhibitor candidates for Parkinson's disease, glioblastoma, and Alzheimer's disease.
Is ProJenX a public or private company?
ProJenX is a private company. It is classified as venture growth investor backed and is currently operating.
When was ProJenX founded?
ProJenX was founded in 2022. It employs 1 to 10 people.
Where is ProJenX based?
ProJenX is headquartered in New Suffolk, United States, in the North America region.
How does ProJenX make money?
One revenue line is on record: drug Development and Commercialization.
Who are ProJenX's main competitors?
Direct peers on record are Ionis Pharmaceuticals, Cytokinetics, AcuraStem and Clene Nanomedicine. Biogen is listed as a broad incumbent. Emerging players are Helixmith, Denali Therapeutics, AB Science, Eledon Pharmaceuticals and Praxis Precision Medicines.
Does ProJenX have an API?
No public API is recorded for ProJenX.
What industry is ProJenX in?
ProJenX's product category is Neurological Therapeutics (ALS). Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2833.